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Abstract 
Background: Few studies have been conducted on the progression of mild Crohn’s disease (CD). We aimed to inves‑
tigate the natural course in mild CD patients with or without bowel damage, to identify predictors of bowel resection 
and to calculate the requirement for rescue medication.
Methods: A total of 104 patients with mild activity (150 < CDAI < 220) with or without bowel damage were identi‑
fied from among 1050 CD patients between January 2008 and May 2014. Univariate and multivariate analysis was 
used to identify factors associated with bowel resection. The cumulative probabilities of bowel resection and rescue 
medication such as steroids or anti‑TNF agents were calculated.
Results: The median follow‑up duration was 28.2 months (IQR 26.7). Cumulative probabilities of bowel resection 
were 0.2, 11.8 and 42.4 % at 1, 3 and 5 years respectively. The CD patients with bowel damage had a higher bowel 
resection rate than those without bowel damage (P < 0.001). The cumulative probabilities of corticosteroid‑require‑
ment were 3.0, 19.6 and 78.4 % of patients at 1, 3 and 5 years, respectively, and 2.1, 11.9 and 56.1 %, in terms of the 
cumulative probabilities of requiring anti‑TNF agents. Patients with elevated CRP (>1.6 mg/dL) were more likely to 
undergo bowel resection (P = 0.032).
Conclusions: Even in CD patients with mild disease activity, the cumulative probability of bowel resection is not 
low if they have bowel damage or elevated CRP at baseline. Mild CD patients with bowel damage or elevated CRP at 
baseline need special attention.
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Background
Crohn’s disease (CD) is a chronic persistent inflammation 
of the gastrointestinal tract of unclear etiology; with time 
it leads to bowel damage (Abraham and Cho 2009).
Global therapeutic strategies for CD patients involve 
step-up or top-down approaches. The step-up strategy 
is adopted individually on a sequential basis. The top-
down strategy involves the early introduction of immu-
nosuppressive and biological treatments to halt the 
progressive bowel damage that occurs during the course 
of the disease in patients with moderate to severe activ-
ity (Beaugerie et  al. 2006; D’Haens et  al. 2008; Dignass 
et  al. 2010). However, an appreciable proportion of 
patients with CD have a mild pattern of disease for 
which budesonide and mesalazine remain the preferred 
treatment (Dignass et  al. 2010). The variable clinical 
spectrum makes it difficult to predict outcomes in mild 
patients with CD (Peyrin-Biroulet et al. 2010b). A better 
understanding of the natural course of CD patients with 
mild disease activity may be helpful in improving their 
management.
Little information is available on the progression of 
mild CD and the factors associated with long-term mild 
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IBD (Cosnes et al. 2012; Reenaers et al. 2016). This study 
was conducted to investigate the course of mild CD in a 
hospital-based cohort. In addition, we identified risk fac-
tors for long-term outcomes such as bowel resection, and 
requirements for rescue medication.
Methods
This study was approved by the Institutional Review 
Board of Asan Medical Center (IRB No 2015-0327) and 
informed consent was waived for this retrospective study.
Study population
This study was performed retrospectively. The patients 
with CD were identified at the Asan Medical Center, 
a tertiary university hospital in Seoul, South Korea, 
between January 2008 and May 2014. CD diagnosis was 
based on conventional clinical, radiologic, endoscopic, 
and histopathologic criteria (Lennard-Jones 1989). We 
identified not only newly-diagnosed mild CD patients 
but also those referred from other hospitals after diag-
nosis. Mild activity was defined by the Crohn’s Disease 
Activity Index (CDAI) score (150  <  CDAI  <  220) with 
no documented history of use of corticosteroids or anti-
TNF agents or bowel surgery at the initial clinic visit. 
The referred patients we required to have mild activity 
at the time of referral and no history of use of steroids, 
immunomodulators or anti-TNF agents. For the patients 
referred after the diagnosis of CD, prior medical informa-
tion was obtained retrospectively by reviewing the medi-
cal records provided, or by interviewing the patients at 
their first visit. A minimum follow-up of 6  months was 
required for inclusion. The diagnosis was systematically 
re-evaluated at each scheduled visit.
Description of variables
Information on age, gender, date of CD diagnosis, time 
between onset of symptoms and diagnosis, follow-up 
duration, date of surgery such as intestinal resection, 
date of disease-related hospitalization, disease location 
and disease behavior were retrospectively extracted from 
the medical records. Disease location and behavior were 
defined according to the Montreal classification (Satsangi 
et al. 2006). Bowel damage was defined as the presence of 
strictures, fistula or abscess on endoscopic or radiologic 
examination. We defined the stricture as luminal narrow-
ing with prestenotic dilatation or with/without obstruc-
tive symptoms in small bowel or colon (Peyrin-Biroulet 
et al. 2010a).
Treatment strategies and follow‑up protocol
Our strategies for treating CD were based on a step-up 
approach, with addition of more potent therapies if and 
when patients became unresponsive to first-line or less 
toxic agents. Oral aminosalicylates were used to induce 
and maintain remission in patients with mild to mod-
erate active disease especially until the mid-2000s (Park 
et  al. 2014). Azathioprine (AZA) or 6-mercaptopurine 
(6-MP) was used as maintenance therapy for steroid-
dependent, steroid-refractory, or fistulizing patients in 
selected cases, mainly after resective surgery, but on a 
more widespread basis from mid to late 2000. To mini-
mize the occurrence of unexpected severe leucopenia 
with AZA, we used the following strategy. AZA was 
started at 25–50  mg/day, and increased by 25–50  mg/
day every 2–4 weeks to a maximum dose of 2.0–2.5 mg/
kg/day while leukocyte levels were being monitored. If 
a rapid decrease in the leukocyte count or leucopenia 
occurred, the AZA therapy dose was decreased or the 
therapy was stopped for a while and restarted at a lower 
dose. The dose of AZA was defined as the maintenance 
dose that induced remission.
The 6-MP dose was converted to an equivalent AZA 
dose by multiplying by 2.08 (Sandborn 2001). Short-
term systemic corticosteroid therapy (oral prednisone 
40–60  mg/day) was used to treat patients with moder-
ate to severe active disease or those who did not respond 
to oral aminosalicylates, then tapered and discontinued 
over 2–3  months. Anti-TNF agents were administered 
to patients with moderate to severe active disease who 
were unresponsive to therapy with corticosteroids and/
or AZA/6-MP from the early-2000s. Surgical procedures 
including bowel resection, strictureplasty, or drainage 
of abscesses were performed to treat medically refrac-
tory disease or complications such as intestinal obstruc-
tion, perforation, abscess, or fistula (Hanauer 2003). The 
laboratory test including erythrocyte sedimentation rate 
(ESR), C-reactive protein (CRP), hematocrit, albumin, 
and CDAI (Best et al. 1979) were measured from the first 
visit after referral or from the time of diagnosis regularly 
during the follow-up period in all the patients.
Primary and secondary endpoint measures
The primary endpoint was the cumulative probability of 
bowel resection. Non-resectional surgery such as seton 
insertion, fistula repair, perianal surgery, or abscess 
drainage was excluded. The secondary endpoints were 
assessed between the groups as follows: cumulative prob-
abilities of (1) steroid requirement, (2) anti-TNF agents 
requirement, and (3) disease-related hospitalization. Fur-
thermore, the cumulative probabilities of the primary 
and secondary endpoints were compared in the patients 
with bowel damage and those without bowel damage.
Statistical analysis
Statistical analyses were performed with SPSS software 
(version 21.0 for Windows; SPSS, Inc., Chicago, IL, USA). 
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Continuous variables were compared using the two-
tailed Student’s t test, and categorical data were com-
pared using a two-tailed χ2 test or Fisher’ exact test. Rates 
of corticosteroid requirement, anti-TNF agents require-
ment, hospitalization, and resectional surgery after treat-
ment were analyzed using Kaplan–Meier survival curves 
for the grouped factors over the intervention period. We 
analyzed factors associated with surgical resection by 
logistic regression analysis. P values <0.05 were consid-
ered to indicate statistical significance. All variables with 
P values of <0.1 were included in the regression analysis.
Results
Baseline characteristics
Figure 1 is a flow chart of the patient selection pathway. 
A total of 104 CD patients with mild disease activity were 
identified, and were classified into those with bowel dam-
age (n = 47) and those without bowel damage (n = 57); 
their baseline characteristics are listed in Table  1. Age 
at diagnosis was higher in the patients with bowel dam-
age than in those without bowel damage. The duration 
of symptoms before diagnosis was longer in the for-
mer group (36.0 vs. 11.1 months; P < 0.001). The cut-off 
point above which levels of CRP were considered high 
was 1.6  mg/dL, which was the median value of CRP in 
these patients. Eighteen out of 19 patients with stenosis 
showed low CRP level (≤1.6 mg/dL) at baseline. Ten out 
of 28 patients with penetrating complications showed 
low CRP level at baseline.
Primary and secondary endpoints
The median follow-up duration was 28.2 months (range 
64.2 or IQR 26.7). Additional rescue therapy was also 
administrated in patients [17 (36 %) with bowel damage, 
21 (37  %) without bowel damage, respectively] during 
their disease course except emergency cases. Unfortu-
nately, the number of patients is too small to measure 
the risk. The cumulative probabilities of bowel resection 
were 0.2, 11.8 and 42.4 % of patients, respectively, at 1, 3 
and 5 years of treatment (Fig. 2a). The cumulative prob-
abilities of corticosteroid-requirement were 3.0, 19.6 
and 78.4  % of patients at 1, 3 and 5  years, respectively, 
(Fig. 2b) and in 2.1, 11.9 and 56.1 %, in terms of cumula-
tive probabilities of anti-TNF agent requirement (Fig. 2c). 
The cumulative probabilities of disease-related hospitali-
zation were 0.0, 22.6 and 87.6 % at 1, 3, at 5 years after the 
start of treatment (Fig. 2d).
Analysis according to the presence of bowel damage 
at enrollment
There were no differences between the patients with 
bowel damage and those without bowel damage regard-
ing the cumulative probabilities of corticosteroid-require-
ment (P =  0.754) (Fig.  3b), anti-TNF agent-requirement 
(P  =  0.925) (Fig.  3c), and disease-related hospitaliza-
tion (P = 0.117) (Fig. 3d). However, a higher proportion 
of those with bowel damage underwent bowel resection 
(P < 0.001) (Fig. 3a).
Factors associated with intestinal resection
Bowel resection was performed in 23 of the 104 (22.1 %) 
patients during follow-up. The reasons for surgery 
were strictures (n  =  5) and penetrating complications 
(n  =  18). None of the patients with strictures under-
went an endoscopic balloon dilatation. Perianal fistula 
was associated with bowel resection in univariate analy-
sis (OR 3.724; 95  % confidence interval 1.330–10.423; 
P = 0.012) and in multivariate analysis (OR 3.885; 95 % 
confidence interval 1.189–12.691; P =  0.025) (Table  2). 
In addition, there were significant associations between 
bowel resection and male gender in multivariate analy-
sis (OR 9.342; 95  % confidence interval 1.028–84.895; 
P  =  0.047) (Table  2). CRP at baseline was associated 
with bowel resection in univariate (OR 1.133; 95 % con-
fidence interval 1.009–1.271; P  =  0.034) (Table  2) and 
multivariate analysis (OR 1.196; 95 % confidence interval 
1.046–1.368; P  =  0.009) (Table  2). However, age, ESR, 
hematocrit, and body mass index (BMI) were not signifi-
cant predictors of bowel resection in univariate analysis 
(Table 2).
Stratified analysis by level of CRP elevation demon-
strated increased bowel resection in those with higher 
CRP (Fig. 4).
Discussion
In our study about one-fifth of patients with mild 
activity underwent bowel resection during follow-up. 
Three-quarters of the patients required corticosteroids 
during their illness, and more than half required anti-
TNF agents. In addition elevated CRP at baseline was 
predictive of intestinal resection.
Fig. 1 Flow diagram of the patient selection process
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Cohort studies indicated that more than half of the 
patients with CD between 1990 and 1994 had a mild 
course of disease during their first 10 years (Froslie et al. 
2007). However, in our study only one-tenth of all CD 
patients had mild CD. The referral bias may contribute to 
the relatively small percentage of mild CD. However, we 
defined mild CD patients with both CDAI and history of 
medication use. We do not think the possibility of mis-
classification of CD patients with mild activity is high.
As far as we know, only one study has described the 
evolution of mild IBD; it analyzed the clinical significance 
and factors associated with inflammatory bowel disease 
that was considered to be mild 1  year after diagnosis 
(Reenaers et al. 2016). In that study, 90 % of CD patients 
lost their mild disease status over time (Reenaers et  al. 
2016).
However, our study differed from that study (Reenaers 
et al. 2016). First, we focused on CD and we assessed dis-
ease activity regularly, using the CDAI, which is a well-
established research tool. As most IBD referral centers in 
Korea have their own outpatient clinic, assessing CDAI 
scores regularly is not difficult. Second, the former study 
defined mild as inflammatory luminal CD without bowel 
damage. We defined mild CD using “regardless of the 
presence of bowel damage” and found that about half of 
the patients with mild activity had bowel damage at base-
line. We evaluated the small bowel and colon at the time 
of the first clinic visit in all patients, using ileocolonos-
copy and CT enterography. Despite demonstrating objec-
tive evidence of bowel damage, about a half of the CD 
patients had mild disease activity. Those with bowel dam-
age had a longer duration of symptoms before diagnosis 
and more often underwent intestinal resectional surgery 
during their disease course. This implies that prolonged 
symptom duration in mild patients with bowel damage 
habituates them to inflammatory signals. These findings 
have also been reported in a study of asymptomatic CD 
patients (Click et al. 2015).
The overall cumulative probability of bowel resection 
was not low in this study, which can be explained by the 
Table 1 Clinical characteristics of mild CD patients according to presence of bowel damage
IQR inter-quartile range, ASA aminosalicylic acid, BMI body mass index, CRP C-reactive protein, ESR erythrocyte sedimentation rate, Hct hematocrit, CDAI Crohn’s 
disease activity index, NA not applicable
Characteristic Total (n = 104) Patients with bowel  
damage (n = 47)
Patients without bowel  
damage (n = 57)
P value
Age at diagnosis, year, median (IQR) 28.0 (11.8) 32.0 (13.0) 24.0 (9.0) 0.047
Gender, (%) 0.067
 Male 85 (81.7) 42 (89.4) 43 (75.4)
 Female 19 (18.3) 5 (8.6) 14 (24.6)
Symptom duration before diagnosis, month, 
median (IQR)
15.9 (40.1) 36.0 (66.9) 11.1 (22.2) <0.001
Location, (%) 0.431
 L1 (ileal) 20 (19.2) 12 (25.5) 8 (14.0)
 L2 (colonic) 4 (3.8) 1 (2.1) 3 (5.3)
 L3 (ileocolonic) 45 (43.3) 19 (40.4) 26 (45.6)
 L4 (only upper GI) 0 (0.0) 0 (0.0) 0 (0.0)
 L1–L4 11 (10.6) 5 (10.6) 6 (10.5)
 L2–L4 0 (0.0) 0 (0.0) 0 (0.0)
 L3–L4 24 (23.1) 10 (21.3) 14 (24.6)
Behavior at diagnosis, (%) 0.002
 B1 (non‑stricturing, non‑penetrating) 23 (22.1) 0 (0.0) 23 (22.1)
 B2 (stricturing) 11 (10.6) 11 (10.6) 0 (0.0)
 B3 (penetrating) 18 (17.3) 18 (17.3) 0 (0.0)
 B1‑P 34 (32.7) 0 (0.0) 34 (32.7)
 B2‑P 8 (7.7) 8 (7.7) 0 (0.0)
 B3‑P 10 (9.6) 10 (9.6) 0 (0.0)
BMI, median (IQR) 19.7 (3.7) 19.2 (3.9) 20.3 (3.6) 0.206
CRP, median (IQR) 1.6 (3.6) 1.6 (3.6) 1.6 (3.6) 0.268
ESR, median (IQR) 38.0 (50.5) 32.0 (49.0) 30.0 (58.0) 0.981
Hct, median (IQR) 39.5 (6.9) 39.1 (7.0) 39.9 (6.9) 0.800
CDAI, median (IQR) 180.4 (36.6) 187.4 (40.2) 177.6 (36.3) 0.975
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enrollment of mild CD patients with bowel damage at base-
line. Of our patients, 2 % had undergone surgical resection 
at 1 year, and 21.8 and 42.4 % at 3 and 5 years, respectively 
(Fig.  2a). Our surgical resection rates differed little from 
the results of the above study (Click et al. 2015) despite the 
mild clinical activity at diagnosis. Bowel resection rates in 
CD patients ranged from 7 to 59 % at 5 years in a recent 
review (Wolters et al. 2004; Chatu et al. 2014). In the pre-
sent study, one-third of the patients received immunomod-
ulators regardless of bowel damage after enrollment.
The cumulative rates of introduction of anti-TNF 
agents were 2.1 and 56.1 % at 1 and 5 years, respectively 
(Fig.  2c), lower than the 23.2 and 67.0  % in a previous 
study (Peyrin-Biroulet et  al. 2011). These findings are 
quite surprising in that anti-TNF agents can be indicated 
in even in mild CD at baseline.
It is important to identify predictive factors at the time 
of diagnosis, and more intensive intervention may be rec-
ommended in selected CD patients with poor prognostic 
factors.
Beaugerie et  al. (2006) reported that age less than 
40  years, the presence of perianal disease, and the need 
for steroid treatment at diagnosis were predicted disabling 
course of CD over subsequent 5 years. C-reactive protein 
(CRP) was only biological parameter to predict a more 
severe clinical course of CD (Henriksen et  al. 2008). In 
this study, most of the identified patients (82.7 %, 86/104) 
were less than 40 years. We excluded the steroid users or 
immunosuppressant users from the cohort initially. Thus, 
we only added the presence of perianal fistula in the uni-
variate and multivariate analysis. (Beaugerie et  al. 2006; 
Henriksen et al. 2008; Cerqueira and Lago 2013).
Fig. 2 The cumulative probabilities of bowel resection (a), steroid requirement (b), anti‑TNF agent requirement (c), and hospitalization (d) in 
patients with mild activity
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We confirmed that patients with bowel damage at diag-
nosis had a higher bowel resection rate than those with-
out bowel damage. In several studies, bowel damage, 
such as stricturing or penetrating behavior, was associ-
ated with increased risk of surgical recurrence (Fowler 
et al. 2014; Sjoberg et al. 2014; Moon et al. 2014).
We demonstrated that patients with elevated base-
line CRP levels had a higher bowel resection rate even 
in patients with mild activity. It is well-known that ele-
vated CRP are regarded as indicators of disease activ-
ity and the predictors of the risk of relapse in patients 
with CD who are in clinical remission (Consigny et  al. 
2006; Desai et  al. 2007; Koelewijn et  al. 2008; Reinisch 
et al. 2012). Moreover, in a subgroup analysis, a signifi-
cant association was found between CRP level at first 
visit and subsequent surgical resection (Henriksen et al. 
2008). Some argues that CRP levels may be confound-
ers with bowel damage in this study. However, Hen-
riksen reported that no differences in CRP levels were 
observed between subgroups of patients categorised 
according to the Vienna classification related to behav-
iour (B1–B3) of the disease, although C-reactive protein 
(CRP) was only biological parameter to predict a more 
severe clinical course of CD (Henriksen et al. 2008). In 
our study, baseline CRP level was not different between 
the patients with bowel damage and those without 
bowel damage. Thus, bowel damage was not included 
into multivariate analysis.
An additional finding was that male gender was asso-
ciated with bowel resection unlike in a previous study 
(Polito et al. 1996). We do not know why male gender is 
associated with bowel resection. However, Korean CD 
Fig. 3 Cumulative probabilities of bowel resection (a), steroid requirement (b), anti‑TNF agent requirement (c), and hospitalization (d) with and 
without bowel damage at diagnosis
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patients have a male predominance (Park et  al. 2014). 
Young female Korean patients are usually reluctant to 
undergo bowel resection scar. These reasons probably 
contribute to the gender difference in bowel resection 
rate.
The major limitation of our study is that it was a ret-
rospective, observational study, which had potential for 
referral bias and confounding factors. Secondly, although 
we aimed to investigate long-term outcomes, the length 
of follow-up achieved was not adequate. Third, we did 
not examine serologic reactivity to bacterial antigens, 
which are well-known predictors of fibrostenosing behav-
ior in Western populations (Dubinsky et al. 2006). How-
ever, more time will be needed to incorporate serological 
tests into clinical practice because of their high cost in 
Korea. Forth, the data on smoking history, endoscopic 
and radiologic findings other than the presence of bowel 
damage was not complete because of the retrospective 
nature of the study. Another limitation comes from the 
small size of the studied population; further prospec-
tive studies with larger numbers of patients are needed. 
Despite of the several limitations, our study may provide 
useful insight into the disease course in mild CD patients, 
given the paucity of knowledge of this matter.
Conclusions
In conclusion, we found that mild CD patients with 
bowel damage at initial evaluation and with elevated CRP 
may have worse long-term outcomes than those without 
bowel damage and with normal CRP levels. Attention 
should be paid to such patients, who may need a different 
therapeutic strategy despite their mild disease activity. 
We suggest that there may be a role for early intervention 
in mild CD.
Authors’ contributions
MSK and KJK contributed to the conception and design of the study. SHP, DHY, 
BDY, JSB, SJM, SKY and JHK were responsible for the acquisition, analysis, and 
interpretation of the data. MSK and KJK drafted the manuscript. All authors 
read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 26 April 2016   Accepted: 16 June 2016
References
Abraham C, Cho JH (2009) Inflammatory bowel disease. N Engl J Med 
361(21):2066–2078. doi:10.1056/NEJMra0804647
Beaugerie L, Seksik P, Nion‑Larmurier I, Gendre JP, Cosnes J (2006) Predic‑
tors of Crohn’s disease. Gastroenterology 130(3):650–656. doi:10.1053/j.
gastro.2005.12.019
Best WR, Becktel JM, Singleton JW (1979) Rederived values of the eight coef‑
ficients of the Crohn’s disease activity index (CDAI). Gastroenterology 
77(4):843–846
Cerqueira RM, Lago PM (2013) Clinical factors predictive of Crohn’s disease 
complications and surgery. Eur J Gastroenterol Hepatol 25(2):129–134. 
doi:10.1097/MEG.0b013e32835a7eed
Chatu S, Subramanian V, Saxena S, Pollok RC (2014) The role of thiopurines in 
reducing the need for surgical resection in Crohn’s disease: a systematic 
Table 2 Univariate and  multivariate analysis of  factors 
at diagnosis related to subsequent surgical resection
ESR erythrocyte sedimentation rate, CRP C-reactive protein, Hct hematocrit, BMI 
body mass index, CDAI Crohn’s disease activity index
Variable OR (95 % CI) P value
Univariate
 Age 1.060 (1.993–1.093) 0.097
 Gender
  Male 6.286 (0.792–49.880) 0.082
  Female
 ESR 1.002 (0.988–1.017) 0.780
 CRP 1.133 (1.009–1.271) 0.034
 Hct 0.968 (0.892–1.051) 0.437
 BMI 0.959 (0.825–1.115) 0.584
 Perianal fistula
  Yes 3.724 (1.330–10.423) 0.012
Multivariate
 Age 1.037 (0.980–1.098) 0.205
 Gender
  Male 9.342 (1.028–84.895) 0.047
  Female
 CRP 1.196 (1.046–1.368) 0.009
 Perianal fistula
  Yes 3.885 (1.189–12.691) 0.025
Fig. 4 Kaplan–Meier bowel resection‑free survival curves in patients 
with mild CD, stratified by low (n = 52) and high (n = 52) CRP level
Page 8 of 8Kwak et al. SpringerPlus  (2016) 5:878 
review and meta‑analysis. Am J Gastroenterol 109(1):23–34. doi:10.1038/
ajg.2013.402 quiz 35
Click B, Vargas EJ, Anderson AM, Proksell S, Koutroubakis IE, Ramos Rivers C, 
Hashash JG, Regueiro M, Watson A, Dunn MA, Schwartz M, Swoger J, 
Baidoo L, Barrie AI, Binion DG (2015) Silent Crohn’s disease: asymptomatic 
patients with elevated C‑reactive protein are at risk for subsequent 
hospitalization. Inflamm Bowel Dis 21(10):2254–2261. doi:10.1097/
mib.0000000000000516
Consigny Y, Modigliani R, Colombel J, Dupas J, Lémann M, Mary J (2006) A 
simple biological score for predicting low risk of short‑term relapse in 
Crohn’s disease. Inflamm Bowel Dis 12(7):551–557
Cosnes J, Bourrier A, Nion‑Larmurier I, Sokol H, Beaugerie L, Seksik P (2012) Fac‑
tors affecting outcomes in Crohn’s disease over 15 years. Gut 61(8):1140–
1145. doi:10.1136/gutjnl‑2011‑301971
Desai D, Faubion WA, Sandborn WJ (2007) Review article: biological activ‑
ity markers in inflammatory bowel disease. Aliment Pharmacol Ther 
25(3):247–255
D’Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De 
Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van de Mierop FJ, 
Coche JC, van der Woude J, Ochsenkuhn T, van Bodegraven AA, Van 
Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P, Feagan BG, Hommes 
D, Belgian Inflammatory Bowel Disease Research Group, North‑Holland 
Gut Club (2008) Early combined immunosuppression or conventional 
management in patients with newly diagnosed Crohn’s disease: 
an open randomised trial. Lancet 371(9613):660–667. doi:10.1016/
S0140‑6736(08)60304‑9
Dignass A, Van Assche G, Lindsay JO, Lemann M, Soderholm J, Colombel JF, 
Danese S, D’Hoore A, Gassull M, Gomollon F, Hommes DW, Michetti P, 
O’Morain C, Oresland T, Windsor A, Stange EF, Travis SP, Cs European, 
Colitis O (2010) The second European evidence‑based consensus on the 
diagnosis and management of Crohn’s disease: current management. J 
Crohns Colitis 4(1):28–62. doi:10.1016/j.crohns.2009.12.002
Dubinsky MC, Lin YC, Dutridge D, Picornell Y, Landers CJ, Farrior S, Wrobel I, 
Quiros A, Vasiliauskas EA, Grill B, Israel D, Bahar R, Christie D, Wahbeh G, 
Silber G, Dallazadeh S, Shah P, Thomas D, Kelts D, Hershberg RM, Elson CO, 
Targan SR, Taylor KD, Rotter JI, Yang H (2006) Serum immune responses 
predict rapid disease progression among children with Crohn’s disease: 
immune responses predict disease progression. Am J Gastroenterol 
101(2):360–367. doi:10.1111/j.1572‑0241.2006.00456.x
Fowler SA, Ananthakrishnan AN, Gardet A, Stevens CR, Korzenik JR, Sands 
BE, Daly MJ, Xavier RJ, Yajnik V (2014) SMAD3 gene variant is a risk factor 
for recurrent surgery in patients with Crohn’s disease. J Crohns Colitis. 
doi:10.1016/j.crohns.2014.01.003
Froslie KF, Jahnsen J, Moum BA, Vatn MH, Group I (2007) Mucosal healing 
in inflammatory bowel disease: results from a Norwegian population‑
based cohort. Gastroenterology 133(2):412–422. doi:10.1053/j.
gastro.2007.05.051
Hanauer SB (2003) Crohn’s disease: step up or top down therapy. Best Pract 
Res Clin Gastroenterol 17(1):131–137
Henriksen M, Jahnsen J, Lygren I, Stray N, Sauar J, Vatn MH, Moum B (2008) 
C‑reactive protein: a predictive factor and marker of inflammation in 
inflammatory bowel disease. Results from a prospective population‑
based study. Gut 57(11):1518–1523. doi:10.1136/gut.2007.146357
Koelewijn CL, Schwartz MP, Samsom M, Oldenburg B (2008) C‑reactive protein 
levels during a relapse of Crohn’s disease are associated with the clinical 
course of the disease. World J Gastroenterol 14(1):85–89
Lennard‑Jones JE (1989) Classification of inflammatory bowel disease. Scand J 
Gastroenterol 24(sup170):2–6
Moon CM, Park DI, Kim ER, Kim YH, Lee CK, Lee SH, Kim JH, Huh KC, Jung SA, 
Yoon SM, Song HJ, Jang HJ, Kim YS, Lee KM, Shin JE (2014) Clinical fea‑
tures and predictors of clinical outcomes in Korean patients with Crohn’s 
disease: a Korean association for the study of intestinal diseases multi‑
center study. J Gastroenterol Hepatol 29(1):74–82. doi:10.1111/jgh.12369
Park SH, Yang SK, Park SK, Kim JW, Yang DH, Jung KW, Kim KJ, Ye BD, Byeon JS, 
Myung SJ, Yoon YS, Yu CS, Kim JH (2014) Long‑term prognosis of Crohn’s 
disease and its temporal change between 1981 and 2012: a hospital‑
based cohort study from Korea. Inflamm Bowel Dis 20(3):488–494. 
doi:10.1097/01.mib.0000441203.56196.46
Peyrin‑Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ (2010a) Early Crohn 
disease: a proposed definition for use in disease‑modification trials. Gut 
59(2):141–147. doi:10.1136/gut.2009.187120
Peyrin‑Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ (2010b) The natural 
history of adult Crohn’s disease in population‑based cohorts. Am J Gas‑
troenterol 105(2):289–297. doi:10.1038/ajg.2009.579
Peyrin‑Biroulet L, Oussalah A, Williet N, Pillot C, Bresler L, Bigard MA (2011) 
Impact of azathioprine and tumour necrosis factor antagonists on the 
need for surgery in newly diagnosed Crohn’s disease. Gut 60(7):930–936. 
doi:10.1136/gut.2010.227884
Polito JM 2nd, Childs B, Mellits ED, Tokayer AZ, Harris ML, Bayless TM (1996) 
Crohn’s disease: influence of age at diagnosis on site and clinical type of 
disease. Gastroenterology 111(3):580–586
Reenaers C, Pirard C, Vankemseke C, Latour P, Belaiche J, Louis E (2016) 
Long‑term evolution and predictive factors of mild inflammatory bowel 
disease. Scand J Gastroenterol 51(6):712–719. doi:10.3109/00365521.201
5.1128965
Reinisch W, Wang Y, Oddens BJ, Link R (2012) C‑reactive protein, an indica‑
tor for maintained response or remission to infliximab in patients with 
Crohn’s disease: a post hoc analysis from ACCENT I. Aliment Pharmacol 
Ther 35(5):568–576
Sandborn WJ (2001) Rational dosing of azathioprine and 6‑mercaptopurine. 
Gut 48(5):591–592
Satsangi J, Silverberg MS, Vermeire S, Colombel JF (2006) The Montreal clas‑
sification of inflammatory bowel disease: controversies, consensus, and 
implications. Gut 55(6):749–753. doi:10.1136/gut.2005.082909
Sjoberg D, Holmstrom T, Larsson M, Nielsen AL, Holmquist L, Ekbom A, Ron‑
nblom A (2014) Incidence and clinical course of Crohn’s disease during 
the first year—results from the IBD Cohort of the Uppsala Region (ICURE) 
of Sweden 2005–2009. J Crohns Colitis 8(3):215–222. doi:10.1016/j.
crohns.2013.08.009
Wolters FL, Russel MG, Stockbrügger RW (2004) Systematic review: has disease 
outcome in Crohn’s disease changed during the last four decades? Ali‑
ment Pharmacol Ther 20(5):483–496
